On March 13th 2026 MAPS received notice that the NIDA Drug Supply Program (NDSP) – which provides qualified researchers with free or low-cost controlled substances, research chemicals, and cannabis products …
Lafayette, CA (March, 11, 2026) — The Multidisciplinary Association for Psychedelic Studies (MAPS), a 501(c)(3) nonprofit advancing research, education, and advocacy around psychedelics and cannabis, …
Vienna, Austria; March 9, 2026 —The Multidisciplinary Association for Psychedelic Studies (MAPS) will send senior academics, advocates, Veterans, and policy experts to the 69th session of the United …
Washington, DC; February 4, 2026 — With the United States in a pivotal election year, the Multidisciplinary Association for Psychedelic Studies (MAPS) released its Policy Guidebook, a robust resource …
February 2, 2026 — The Multidisciplinary Association for Psychedelic Studies (MAPS) announces a formal research partnership with Columbia University to study how practitioners are facilitating MDMA-assisted …
On January 30, 2026, the Multidisciplinary Association for Psychedelic Studies (MAPS) submitted MJP2 Protocol Amendment 4, Version 1 (A4V1) to the U.S. Food and Drug Administration (FDA) for review. …
January 14, 2026 — In October 2025, Joe Green and Miriam Volat resigned their positions as members of the MAPS Board of Directors. Mr. Green joined the MAPS board in December 2020 and — among other …
On January 13, 2026, the Multidisciplinary Association for Psychedelic Studies (MAPS) submitted the 2025 Cannabis Data Safety Update Report (DSUR) to the U.S. Food and Drug Administration (FDA). The …
ICEERS’ psychedelic research study, Keeping the Candles Burning: Empowering Peacemakers in Dark Times, was supported through a MAPS grant as part of our ongoing commitment to advancing multidisciplinary …
December 23, 2025 — The Multidisciplinary Association for Psychedelic Studies (MAPS) announced the completion of a therapy training initiative supporting clinicians participating in a Department of Defense …
The executive order to reschedule cannabis marks a symbolic victory and a recalibration of decades of federal misclassification. Reclassifying cannabis as a Schedule III substance is a long-overdue acknowledgment …
Using funding provided by the Ohio Department of Behavioral Health, the Center for Psychedelic Drug Research and Education (CPDRE) will equip more than 127,000 Ohio professionals with skills in psychedelic …
